港股异动 | 英硅智能(03696)涨超9% ISM8969/HT-001已获NMPA临床试验批件拟用于帕金森病治疗

智通财经08-07

智通财经APP获悉，英硅智能(03696)涨超9%，截至发稿，涨8.1%，报44.3港元，成交额5.41亿港元。

消息面上，近日，据英硅智能官微消息，英硅智能宣布，公司与衡泰生物共同开发的创新口服NLRP3抑制剂ISM8969/HT-001已获得中国国家药品监督管理局(NMPA)临床试验批件，拟用于帕金森病治疗。

在2026年6月宣布完成澳洲I期临床首例参与者给药后，该批件标志着中国和澳大利亚两地平行临床评估的正式开启。本次临床研究旨在评估ISM8969/HT-001在健康参与者群体中的安全性、耐受性、药代动力学(PK)和药效动力学(PD)特征，以及在帕金森病患者中的初步疗效，为其后续临床开发奠定基础。

此前，英硅智能于2026年1月宣布与复星健康资本旗下深圳鹏复基金与复星医药的被投企业衡泰生物(Hygtia Therapeutics)达成独家授权与合作协议，共同推进ISM8969/HT-001的全球开发。根据协议，双方各持有该项目50%全球权益，英硅智能有权获得逾5亿港币的预付款及里程碑付款。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2657691079?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-08-07 14:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2657691079","market":"us","top_or_hot":-1,"title":"港股异动 | 英硅智能(03696)涨超9% ISM8969/HT-001已获NMPA临床试验批件 拟用于帕金森病治疗","media":"智通财经","content":"<html><body><p>智通财经APP获悉，英硅智能(03696)涨超9%，截至发稿，涨8.1%，报44.3港元，成交额5.41亿港元。</p><p>消息面上，近日，据英硅智能官微消息，英硅智能宣布，公司与衡泰<a href=\"https://laohu8.com/S/000504\">生物</a>共同开发的创新口服NLRP3抑制剂ISM8969/HT-001已获得中国国家药品监督管理局(NMPA)临床试验批件，拟用于帕金森病治疗。</p><p>在2026年6月宣布完成澳洲I期临床首例参与者给药后，该批件标志着中国和澳大利亚两地平行临床评估的正式开启。本次临床研究旨在评估ISM8969/HT-001在健康参与者群体中的安全性、耐受性、药代动力学(PK)和药效动力学(PD)特征，以及在帕金森病患者中的初步疗效，为其后续临床开发奠定基础。</p><p>此前，英硅智能于2026年1月宣布与<a href=\"https://laohu8.com/S/02196\">复星</a>健康资本旗下深圳鹏复基金与<a href=\"https://laohu8.com/S/600196\">复星医药</a>的被投企业衡泰生物(Hygtia Therapeutics)达成独家授权与合作协议，共同推进ISM8969/HT-001的全球开发。根据协议，双方各持有该项目50%全球权益，英硅智能有权获得逾5亿港币的预付款及里程碑付款。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 英硅智能(03696)涨超9% ISM8969/HT-001已获NMPA临床试验批件 拟用于帕金森病治疗</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 英硅智能(03696)涨超9% ISM8969/HT-001已获NMPA临床试验批件 拟用于帕金森病治疗\n</h2>\n\n<h4 class=\"meta\">\n\n</h4>\n\n</header>\n<article>\n<html><body><p>智通财经APP获悉，英硅智能(03696)涨超9%，截至发稿，涨8.1%，报44.3港元，成交额5.41亿港元。</p><p>消息面上，近日，据英硅智能官微消息，英硅智能宣布，公司与衡泰<a href=\"https://laohu8.com/S/000504\">生物</a>共同开发的创新口服NLRP3抑制剂ISM8969/HT-001已获得中国国家药品监督管理局(NMPA)临床试验批件，拟用于帕金森病治疗。</p><p>在2026年6月宣布完成澳洲I期临床首例参与者给药后，该批件标志着中国和澳大利亚两地平行临床评估的正式开启。本次临床研究旨在评估ISM8969/HT-001在健康参与者群体中的安全性、耐受性、药代动力学(PK)和药效动力学(PD)特征，以及在帕金森病患者中的初步疗效，为其后续临床开发奠定基础。</p><p>此前，英硅智能于2026年1月宣布与<a href=\"https://laohu8.com/S/02196\">复星</a>健康资本旗下深圳鹏复基金与<a href=\"https://laohu8.com/S/600196\">复星医药</a>的被投企业衡泰生物(Hygtia Therapeutics)达成独家授权与合作协议，共同推进ISM8969/HT-001的全球开发。根据协议，双方各持有该项目50%全球权益，英硅智能有权获得逾5亿港币的预付款及里程碑付款。</p></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://www.zhitongcaijing.com/content/detail/1477206.html\">智通财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KCAI","symbol_name":"KraneShares China Alpha Index ETF","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1477206.html","article_id":"2657691079","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2657691079","pubTimestamp":1786082650,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，英硅智能涨超9%，截至发稿，涨8.1%，报44.3港元，成交额5.41亿港元。消息面上，近日，据英硅智能官微消息，英硅智能宣布，公司与衡泰生物共同开发的创新口服NLRP3抑制剂ISM8969/HT-001已获得中国国家药品监督管理局临床试验批件，拟用于帕金森病治疗。此前，英硅智能于2026年1月宣布与复星健康资本旗下深圳鹏复基金与复星医药的被投企业衡泰生物达成独家授权与合作协议，共同推进ISM8969/HT-001的全球开发。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"KCAI":"KraneShares China Alpha Index ETF","BK1141":"生命科学工具和服务","BK1612":"加密货币概念","IBRN":"iShares Neuroscience and Healthcare ETF","01611":"新火集团","BK4588":"碎股","MDTX":"Corgi MediaTek 2x Daily ETF","PSYK":"PSYK ETF","BK4181":"酒店及度假村房地产投资信托","VXUS":"国际股票ETF-Vanguard","BK4585":"ETF&股票定投概念","BK4218":"酒店及度假村房地产信托","IBBQ":"Invesco Nasdaq Biotechnology ETF","BMED":"iShares Health Innovation Active ETF","03696":"英矽智能","BK1167":"电子制造服务","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF"},"translate_title":"Hong Kong stock changes | Yingsi Intelligent (03696) rose more than 9% ISM8969/HT-001 has been approved by NMPA for clinical trials and is intended to be used for the treatment of Parkinson's disease","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBBJ":1.5,"MDTX":1.5,"PSYK":1.5,"HT":1.5,"IBRN":1.5,"03696":1.5,"VXUS":1.5,"KCAI":1.5,"01611":1.5,"IBBQ":1.5,"BMED":1.5},"content_text":"智通财经APP获悉，英硅智能(03696)涨超9%，截至发稿，涨8.1%，报44.3港元，成交额5.41亿港元。消息面上，近日，据英硅智能官微消息，英硅智能宣布，公司与衡泰生物共同开发的创新口服NLRP3抑制剂ISM8969/HT-001已获得中国国家药品监督管理局(NMPA)临床试验批件，拟用于帕金森病治疗。在2026年6月宣布完成澳洲I期临床首例参与者给药后，该批件标志着中国和澳大利亚两地平行临床评估的正式开启。本次临床研究旨在评估ISM8969/HT-001在健康参与者群体中的安全性、耐受性、药代动力学(PK)和药效动力学(PD)特征，以及在帕金森病患者中的初步疗效，为其后续临床开发奠定基础。此前，英硅智能于2026年1月宣布与复星健康资本旗下深圳鹏复基金与复星医药的被投企业衡泰生物(Hygtia Therapeutics)达成独家授权与合作协议，共同推进ISM8969/HT-001的全球开发。根据协议，双方各持有该项目50%全球权益，英硅智能有权获得逾5亿港币的预付款及里程碑付款。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2657691079","isCrawlerRequest":true}